Top

Investigational New Drugs

Published in:

01-06-2015 | LETTER TO THE EDITOR

Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer?

Authors: Robert A. Newman, Peiying Yang

Published in: Investigational New Drugs | Issue 3/2015

Excerpt

Dear Sir: …

Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N, Newman RA (2009) Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na, K-ATPase α subunits as drug targets. Mol Cancer Ther 8(8):2319–2328. doi:10.1158/1535-7163.mct-08-1085 CrossRefPubMed

Calderon-Montano JM, Burgos-Moron E, Orta ML, Mateos S, Lopez-Lazaro M (2013) A hydroalcoholic extract from the leaves of Nerium oleander inhibits glycolysis and induces selective killing of lung cancer cells. Planta Med 79(12):1017–1023. doi:10.1055/s-0032-1328715 CrossRefPubMed

Sreenivasan Y, Sarkar A, Manna SK (2003) Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 66(11):2223–2239CrossRefPubMed

Lee S, Lee Y, Choi YJ, Han KS, Chung HW (2014) Cyto-/genotoxic effects of the ethanol extract of Chan Su, a traditional Chinese medicine, in human cancer cell lines. J Ethnopharmacol 152(2):372–376CrossRefPubMed

Hong DS, Henary H, Falchook GS, Naing A, Fu S, Moulder S, Wheler JJ, Tsimberidou A, Durand JB, Khan R, Yang P, Johansen M, Newman RA, Kurzrock R (2014) First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-kappaBeta and p70s6k, in patients with advanced solid tumors. Invest New Drugs. doi:10.1007/s10637-014-0127-0 PubMedCentral

Title: Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer?
Authors: Robert A. Newman
Peiying Yang
Publication date: 01-06-2015
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2015
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-015-0208-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2015

The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients

Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors

Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro

Keynote webinar | Spotlight on antibody–drug conjugates in cancer